Pathophysiology of thrombosis in myeloproliferative neoplasms

Raffaele Landolfi, Leonardo Di Gennaro

Research output: Contribution to journalArticle

22 Citations (Scopus)


Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that of subjects with polycythemia vera (PV) and essential thrombocythemia (ET) has significantly increased over the last three decades, largely due to the use of cytoreductive treatments. Currently, polycythemia vera and essential thrombocythemia are considered relatively benign diseases in which the main objective of treatment strategy is the prevention of thrombotic events. Widespread use of routine hematologic screening and novel diagnostic tools greatly facilitate disease recognition and treatment.
Original languageEnglish
Pages (from-to)183-186
Number of pages4
Publication statusPublished - 2011


  • Myeloproliferative Disorders
  • Thrombosis


Dive into the research topics of 'Pathophysiology of thrombosis in myeloproliferative neoplasms'. Together they form a unique fingerprint.

Cite this